Cantor Fitzgerald reiterates Overweight on Regeneron stock at $800

Regeneron reported an expected IPR&D charge of ~$102M (~- $0.81 EPS impact) and announced a collaboration with TriNetX of up to $200M, while shares trade around $755–760 (market cap ~$78B) and are +35% over six months, ~7% below the $821 52-week high. FDA approved extended dosing intervals for EYLEA HD (injections as infrequently as 2–3 times annually), and multiple firms reiterated/upgraded targets (Cantor Fitzgerald OW $800 PT; Raymond James Outperform $910 PT; Bernstein $921 PT). Cantor expects near-term fianlimab data will overshadow Q1 2026 results, forecasting a lower-impact quarter (EYLEA HD largely in-line, modest Dupixent miss) and sees data timing and mid-stage program visibility as primary near-term share drivers.

Analysis

Extended-dosing dynamics in retinal franchises create a durable but subtle reshaping of revenue per patient: fewer injections compress headline volume growth while boosting per-patient lifetime margins and bargaining power with payers. That structurally favors companies that can monetize longer intervals via premium pricing and real-world evidence, and it erodes the growth runway for undifferentiated anti‑VEGF incumbents and some ancillary service providers dependent on injection frequency.

A near-term R&D charge and incremental investment in real-world data capabilities recalibrates capital allocation risk — expect management to prioritize programs with clearer payback curves and to use RWE as a lever in label expansion and payer negotiations. Regulatory interactions around competing immunology mechanisms (e.g., IL-33 pathway successes) are now asymmetric catalysts: positive comparator data can either legitimize a class and lift the whole cohort or sharpen the FDA’s benefit-risk bar and narrow label expectations for rivals.

Positioning should therefore bifurcate: short-duration, asymmetric option exposure into upcoming regulatory/data milestones; and balanced equity exposure to capture longer-term margin upside from dosing durability and RWE-driven label expansion. The highest-information windows are the next 6–12 months around mid-stage readouts and regulator meetings — expect realized volatility to spike and a potential +/-15–30% re-rating on binary outcomes, while negative readouts would likely be priced in over 3–6 months unless accompanied by broader class-level implications.

Key Decisions for Investors

• Long REGN via 9–12 month calls (buy 10% OTM LEAPS): size 1–2% notional of portfolio. Rationale: asymmetric upside into mid-stage readouts and further RWE wins; plan to sell into a 20–30% move or roll if data is delayed. Downside: entire premium at risk if clinical/regulatory outcome is negative.
• Equity pair — long REGN / short AZN, equal dollar, 6-month horizon, position size 1% net exposure: expresses conviction that dosing durability + RWE will be underappreciated vs. immunology headline risk. Set stop-loss at 12% adverse move on the pair; target 15–25% relative outperformance.
• Implement a costless collar on existing REGN exposure (buy 6-month 20% OTM puts, sell 6-month 25% OTM calls): protects against binary downside from regulatory or clinical setbacks while giving up some upside. Appropriate for core holders who want to monetize realized volatility into the next set of catalysts.
• Income play: sell 6–8 week puts ~7–10% OTM on REGN to collect premium into expected quiet quarters; allocate small size (0.5–1% of portfolio) and be ready to convert to long equity if assigned. Risk: assignment at strike during a negative surprise — size accordingly and collateralize.